Kyle McHugh, Ben Vizvary, Chris Thomas, Emily Binger, Amber Harezlak, Frank Gallina, Daniel Lewis, Jocelyn Hirsch, Patrick Loughery, Polina Liberman
February 23, 2026
Kirkland Advises TerSera Therapeutics on Sale of Infusion Specialty Therapies Business Unit to ESTEVE
1 min
AI-made summary
- • Kirkland & Ellis advised TerSera Therapeutics LLC on an agreement for ESTEVE to acquire TerSera's Infusion Specialty Therapies Business Unit (IST). • The IST business unit includes two specialty medications: Prialt® (ziconotide intrathecal infusion) and Quzyttir® (cetirizine hydrochloride injection). • The transaction is expected to close in the first quarter of 2026, pending regulatory clearances. • The Kirkland team involved lawyers specializing in corporate, technology & intellectual property, debt finance, and tax matters.
Kirkland & Ellis advised TerSera Therapeutics LLC, a biopharmaceutical company with a focus on oncology and rare diseases, on an agreement whereby ESTEVE will acquire TerSera's Infusion Specialty Therapies Business Unit (IST). TerSera's IST business unit includes two specialty medications, Prialt® (ziconotide intrathecal infusion) and Quzyttir® (cetirizine hydrochloride injection). The transaction is expected to close in the first quarter of 2026, subject to regulatory clearances. Read the transaction press release The Kirkland team included corporate lawyers Kyle McHugh, Ben Vizvary, Chris Thomas and Emily Binger; technology & intellectual property lawyers Amber Harezlak, Frank Gallina and Daniel Lewis; debt finance lawyers Jocelyn Hirsch and Patrick Loughery; and tax lawyer Polina Liberman.
Article Author
Kyle McHugh, Ben Vizvary, Chris Thomas, Emily Binger, Amber Harezlak, Frank Gallina, Daniel Lewis, Jocelyn Hirsch, Patrick Loughery, Polina Liberman
The Sponsor